Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a safer dose of an old drug shield vulnerable children from deadly fungal infections?

NCT ID NCT07725263

Recruiting now Disease control Sponsor: Haikou Affiliated Hospital of Central South University Xiangya School of Medicine Source: ClinicalTrials.gov ↗

First seen Jul 24, 2026 · Last updated Jul 24, 2026

Summary

This trial tests whether a low dose of the antifungal drug liposomal amphotericin B can prevent invasive fungal infections in children aged 3 to 17 who have prolonged neutropenia (very low white blood cell counts) after cancer treatment or stem cell transplant. The drug is given intravenously once daily to children already at high risk. Researchers will track how many develop a proven or probable fungal infection, as well as side effects, to see if this approach is both effective and safer than standard doses.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a low-dose form of the antifungal drug liposomal amphotericin B, given intravenously once daily
What this could lead to
If it works, this could offer a safer way to prevent life-threatening fungal infections in children with weakened immune systems.
What could go wrong
This is a small, single-center study with only 30 participants, so results may not apply broadly. The drug can still cause kidney problems or other side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GRAFT VS HOST DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

graft versus host disease hematopoietic and lymphoid system neoplasm Invasive Fungal Infections neutropenia systemic mycosis thalassemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GRAFT VS HOST DISEASE HEMATOPOIETIC STEM CELL TRANSPLANTATION INVASIVE FUNGAL INFECTIONS NEUTROPENIA THALASSEMIA

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Haikou Affiliated Hospital of Central South University Xiangya School of Medicine

    RECRUITING

    Haikou, Hainan, 570208, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.